Chief Executive Officer, Solventum
Appears in 1 story
Active
The FDA cleared Solventum to use its Restrata synthetic tissue matrix under its V.A.C. negative pressure wound therapy — the first clearance combining the two technologies. Clinicians can now place a fully synthetic, resorbable scaffold beneath a vacuum dressing that stays on for up to seven days.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
